Trial Profile
A Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic Erythroderma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Erythrodermic psoriasis; Pustular psoriasis
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 01 Jun 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI132057)
- 23 Apr 2016 Results published in the British Journal of Dermatology
- 23 Jul 2015 Results published in a Kyowa Hakko Kirin media release.